Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).

Trial Details

NCT ID
NCT05502315
Phase
PHASE2
Sponsor
Rana McKay, MD
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • Cabozantinib
  • Nivolumab
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Dallas, Texas, United States|32.78306,-96.80667
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Subjects must meet all of the following applicable inclusion criteria to participate in this study:
  • Willing and able to provide, or have a legally authorized representative provide, written informed consent and HIPAA authorization for the release …
  • Males 18 years of age and above.
  • Histological or cytological proof of prostate adenocarcinoma or mixed adenocarcinoma/neuroendocrine tumors. Pure small cell of the prostate is not …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →